Analyst maintains OW rating on Stoke Therapeutics as P3 EMPEROR study design finalized

EditorRachael Rajan
Published 2025-01-08, 09:00 a/m
STOK
-

On Wednesday, Cantor Fitzgerald reiterated an Overweight rating on Stoke Therapeutics (NASDAQ:STOK), following the company's announcement of a finalized Phase 3 EMPEROR study design for zorevunersen (STK-001), aimed at treating Dravet syndrome (DS).

The study design received regulatory alignment with the FDA, EMA, and PMDA, signaling a potential for differentiated clinical value in DS. Despite Stoke Therapeutics' shares falling approximately 15% recently, Cantor Fitzgerald perceives this as a market inefficiency and an opportunity for investors with a long-term horizon.

The EMPEROR Phase 3 trial is a single global study that has been informed by previous data and is designed to demonstrate differentiation in DS treatment, on top of the best standard of care anti-seizure medication (ASM). The trial includes a 52-week blind period to preserve the integrity of the results for both primary and secondary endpoints. Cantor Fitzgerald notes the trial design simplifies some aspects, such as reducing the number of loading doses and maintaining a single study instead of multiple parallel studies, which could facilitate rapid enrollment and potential partnerships.

Cantor Fitzgerald highlighted the strategic planning behind the EMPEROR trial, emphasizing the potential for the study to establish zorevunersen as a new standard of care in young patients, with the possibility of near-gene-therapy-like pricing and pharmacoeconomic value. The firm suggests that the trial's design reduces risk and may accelerate patient enrollment and partnering opportunities.

Stoke Therapeutics reported having approximately $269 million on its balance sheet, which Cantor Fitzgerald believes positions the company well to fund the EMPEROR trial. The firm anticipates that Stoke will reach enrollment milestones and possibly complete the trial in 2026, viewing the current dip in stock price as a buying opportunity for long-term investors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.